Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer

Mirat Shah1, Mallorie H Fiero1, Joyce Cheng1

  • 1Mirat Shah, MD, Mallorie H. Fiero, PhD, Joyce Cheng, PhD, Ting-Yu Chen, PhD, and Gwynn Ison, MD, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD; Richard Pazdur, MD, and Laleh Amiri-Kordestani, MD, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD.

Abstract

No abstract available in PubMed .